BCM
MLNT

BlueCrest Capital Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

BlueCrest Capital Management’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,120
Closed -$42K – 1658
2018
Q3 		$42K Buy
+2,120
New +$53.6K ﹤0.01% 1451

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlueCrest Capital Management's MLNT Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2018, closing a stake of 2,120 shares — an estimated $42K sold.

BlueCrest Capital Management first reported a position in MLNT in Q3 2018 and held it in 1 quarter. The position peaked at $42K in Q3 2018. 77 funds tracked by Wall St. Rank hold MLNT as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 2,120 Melinta Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $42K.
  • BlueCrest Capital Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Melinta Therapeutics, Inc. Common Stock position peaked at $42K in Q3 2018.
  • 77 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.